Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody.

Authors :: Huang J
Wang Y
Zhang H
Hu X
Wang P
Cai W
Yuan Y
Zeng H
Zhang J
Kong W
Huang Y
Wang S
Guo J
Wei Q
Xue W
Source :: Cancer communications (London, England) [Cancer Commun (Lond)] 2021 Oct; Vol. 41 (10), pp. 1071-1074. Date of Electronic Publication: 2021 Aug 07.
Publication Year :: 2021

Subjects :: Axitinib therapeutic use
Humans
Protein Kinase Inhibitors adverse effects
Carcinoma, Renal Cell drug therapy
Kidney Neoplasms drug therapy

Full Text Access

Tools